The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - MedSIR; Thummi
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Daiichi Sankyo Pharmaceutical; Eisai; GlaxoSmithKline; Lilly O.; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Research Funding - AB Science (Inst); Abbvie (Inst); Abraxis BioScience (Inst); Amgen (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Pharmaceutical (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Henlius (Inst); ImClone Systems (Inst); Leo Pharma (Inst); Lilly O. (Inst); Medivation (Inst); Merck (Inst); Merck KGaA (Inst); Merrimack (Inst); Millennium (Inst); Mylan (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); Polyphor (Inst); Roche/Genentech (Inst); Sanofi (Inst); Shanghai Henlius Biotech (Inst); Taiho Pharmaceutical (Inst)
Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis.
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Baxter (Inst); Daiji Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Medac (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst)
 
David Pérol
Honoraria - AstraZeneca; BMS; DAIICHI SANKYO; Lilly; MSD; Novartis; Roche; TAKEDA
Travel, Accommodations, Expenses - Roche
 
Erica L. Mayer
Consulting or Advisory Role - AstraZeneca; Diaccurate; Gilead Sciences; Lilly; Novartis
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
 
Arnd Nusch
Consulting or Advisory Role - Amgen; Novartis
Research Funding - Novartis
Travel, Accommodations, Expenses - Novartis
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
 
Carlos Barrios
No Relationships to Disclose
 
Thomas E. Delea
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Akcea Therapeutics (Inst); Akebia Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Alkermes (Inst); Amgen (Inst); Asahi Kasei (Inst); BTG (Inst); Celgene (Inst); Cytokinetics (Inst); Dynavax Technologies (Inst); Eidos Therapeutics (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Global Blood Therapeutics (Inst); GRAIL (Inst); InterMune (Inst); Ionis Pharmaceuticals (Inst); LEO Pharma (Inst); Merck (Inst); Merck (Inst); MinervaX (Inst); Moderna Therapeutics (Inst); Myovant Sciences (Inst); Neurelis (Inst); Novartis (Inst); Novartis Canada Pharmaceuticals Inc (Inst); OncImmune (Inst); Otsuka (Inst); Pfizer (Inst); Regeneron (Inst); Respirtech (Inst); Sanofi (Inst); Sanofi Pasteur (Inst); Seagen (Inst); Tactile Medical (Inst); Taiho Oncology (Inst); Takeda (Inst); Vertex (Inst)
 
Tonatiuh Romero Salas
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Manik Kalra
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Rhea Gupta
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Purnima Pathak
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche